Top

Published in:

Open Access 01-12-2023 | Review

Role of telitacicept in the treatment of IgA nephropathy

Authors: Lijun Wu, Xinru Du, Xuehong Lu

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

IgA nephropathy (IgAN) is the most common primary glomerular disease in the world, and up to 40% of patients with IgAN develop end-stage renal disease (ESRD). At present, an increasing amount of evidence indicates that the pathogenesis of IgAN is related to autoimmunity. In recent years, several studies have shown that B cell activating factors (BAFF), also known as B lymphocyte stimulators (BLyS), and proliferation-inducing ligand APRIL are extremely important for the activation of autoimmune signalling pathways, which have become key targets for the treatment of IgAN. As a dual-target biological agent, telitacicept can inhibit both BLyS and APRIL cytokines, improve the function of renal immune complexes, and reduce haematuria and proteinuria, which play important roles in IgAN pathogenesis and long-term prognosis. This article reviews the role of telitacicept in IgA nephropathy and discusses its potential for use in the treatment of IgAN and other autoimmune diseases where pathogenesis is driven by B cells.

D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004;24(3):179–96. https://doi.org/10.1016/j.semnephrol.2004.01.001.CrossRefPubMed

Monteiro RC, Suzuki Y. Are there animal models of IgA nephropathy? Semin Immunopathol. 2021;43(5):639–48. https://doi.org/10.1007/s00281-021-00878-5.CrossRefPubMed

Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018;38(5):435–42. https://doi.org/10.1016/j.semnephrol.2018.05.013.CrossRefPubMed

Hu R, Quan S, Wang Y, et al. Spectrum of biopsy proven renal diseases in Central China: a 10-year retrospective study based on 34,630 cases. Sci Rep. 2020;10(1):10994. https://doi.org/10.1038/s41598-020-67910-w.CrossRefPubMedCentralPubMed

O’Shaughnessy MM, Hogan SL, Thompson BD, Coppo R, Fogo AB, Jennette JC. Glomerular disease frequencies by race, sex and region: results from the International kidney biopsy survey. Nephrol Dial Transpl. 2018;33(4):661–9. https://doi.org/10.1093/ndt/gfx189.CrossRef

Zhou FD, Zhao MH, Zou WZ, Liu G, Wang H. The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese centre. Nephrol Dial Transpl. 2009;24(3):870–6. https://doi.org/10.1093/ndt/gfn554.CrossRef

Cheung AK, Chang TI, Cushman WC, et al. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3):S1–87.CrossRef

Cheung CK, Rajasekaran A, Barratt J, Rizk DV. An update on the current state of management and clinical trials for IgA nephropathy. J Clin Med. 2021;10(11):2493.CrossRefPubMedCentralPubMed

Dhillon S. Telitacicept: first approval. Drugs. 2021;81(14):1671–5. https://doi.org/10.1007/s40265-021-01591-1.CrossRefPubMed

10.

Fan Y, Gao D, Zhang Z. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus. Drugs Today (Barcelona, Spain : 1998). 2022;58(1):23–32. https://doi.org/10.1358/dot.2022.58.1.3352743.CrossRef

11.

Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol. 2021;43(6):666–73. https://doi.org/10.1080/08923973.2021.1973493.CrossRefPubMed

12.

Lv J, Liu L, Hao C, Li G, Fu P, Xing G, Zheng H, Chen N, Wang C, Luo P, Xie D, Zuo L, Li R, Mao Y, Dong S, Zhang P, Zheng H, Wang Y, Qin W, Wang W, Li L, Jiao W, Fang J, Zhang H. Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep 2022;8(3):499–506. https://doi.org/10.1016/j.ekir.2022.12.014. PMID: 36938094; PMCID: PMC10014376.

13.

Selvaskandan H, Barratt J, Cheung CK. Immunological drivers of IgA nephropathy: exploring the mucosa-kidney link. Int J Immunogenet. 2022;49(1):8–21. https://doi.org/10.1111/iji.12561.CrossRefPubMed

14.

Pattrapornpisut P, Avila-Casado C, Reich HN. IgA nephropathy: core curriculum 2021. Am J Kidney Dis. 2021;78(3):429–41. https://doi.org/10.1053/j.ajkd.2021.01.024.CrossRefPubMed

15.

Chang S, Li XK. The role of immune modulation in pathogenesis of IgA nephropathy. Front Med. 2020;7:92. https://doi.org/10.3389/fmed.2020.00092.CrossRef

16.

Diamond G, Beckloff N, Weinberg A, Kisich KO. The roles of antimicrobial peptides in innate host defense. Curr Pharm Des. 2009;15(21):2377–92. https://doi.org/10.2174/138161209788682325.CrossRefPubMedCentralPubMed

17.

Wang M, Lv J, Zhang X, Chen P, Zhao M, Zhang H. Secondary IgA nephropathy shares the same immune features with primary IgA nephropathy. Kidney Int Rep. 2020;5(2):165–72. https://doi.org/10.1016/j.ekir.2019.10.012.CrossRefPubMed

18.

Feehally J, Beattie TJ, Brenchley PE, Coupes BM, Mallick NP, Postlethwaite RJ. Sequential study of the IgA system in relapsing IgA nephropathy. Kidney Int. 1986;30(6):924–31. https://doi.org/10.1038/ki.1986.274.CrossRefPubMed

19.

Macpherson Andrew J, Gatto D, Sainsbury E, Harriman Gregory R, Hengartner H, Zinkernagel Rolf M. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science. 2000;288(5474):2222–6. https://doi.org/10.1126/science.288.5474.2222.CrossRef

20.

Rollino C, Vischini G, Coppo R. IgA nephropathy and infections. J Nephrol. 2016;29(4):463–8. https://doi.org/10.1007/s40620-016-0265-x.CrossRefPubMed

21.

Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF, APRIL and human B cell disorders. Semin Immunol. 2006;18(5):305–17. https://doi.org/10.1016/j.smim.2006.04.004.CrossRefPubMed

22.

Mackay F, Silveira PA, Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol. 2007;19(3):327–36. https://doi.org/10.1016/j.coi.2007.04.008.CrossRefPubMed

23.

Cancro MP, D’Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009;119(5):1066–73. https://doi.org/10.1172/JCI38010.CrossRefPubMedCentralPubMed

24.

Dorner T, Kinnman N, Tak PP. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Therap. 2010;125(3):464–75. https://doi.org/10.1016/j.pharmthera.2010.01.001.CrossRef

25.

Li WW, Peng XF, Liu YY, et al. TLR9 and BAFF: Their expression in patients with IgA nephropathy. Mol Med Rep. 2014;10(3):1469–74. https://doi.org/10.3892/mmr.2014.2359.CrossRefPubMed

26.

McCarthy DD, Kujawa J, Wilson C, et al. Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest. 2011;121(10):3991–4002. https://doi.org/10.1172/jci45563.CrossRefPubMedCentralPubMed

27.

Patel DR, Wallweber HJ, Yin J, et al. Engineering an APRIL-specific B cell maturation antigen. J Biol Chem. 2004;279(16):16727–35. https://doi.org/10.1074/jbc.M312316200.CrossRefPubMed

28.

Matthes T, Dunand-Sauthier I, Santiago-Raber ML, et al. Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. Blood. 2011;118(7):1838–44. https://doi.org/10.1182/blood-2011-01-332940.CrossRefPubMed

29.

Zhai YL, Zhu L, Shi SF, Liu LJ, Lv JC, Zhang H. Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy. Medicine. 2016;95(11): e3099. https://doi.org/10.1097/MD.0000000000003099.CrossRefPubMedCentralPubMed

30.

Muto M, Manfroi B, Suzuki H, et al. Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center B cells in IgA nephropathy. J Am Soc Nephrol. 2017;28(4):1227–38. https://doi.org/10.1681/asn.2016050496.CrossRefPubMed

31.

Nakayamada S, Tanaka Y. BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. Inflamm Regener. 2016;36:6. https://doi.org/10.1186/s41232-016-0015-4.CrossRef

32.

Nishiyama A, Konishi Y, Ohashi N, et al. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrol Dial Transplant. 2011;26(1):170–7. https://doi.org/10.1093/ndt/gfq371.CrossRefPubMed

33.

Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DR. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2001;100(4s):S1-s276. https://doi.org/10.1016/j.kint.2021.05.021.CrossRef

34.

Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225–36. https://doi.org/10.1056/NEJMoa1415463.CrossRefPubMed

35.

Ji L, Chen XL, Zhong X, et al. Astragalus membranaceus up-regulate Cosmc expression and reverse IgA dys-glycosylation in IgA nephropathy. Bmc Complem Altern Med. 2014. https://doi.org/10.1186/1472-6882-14-195.CrossRef

36.

Heerspink HJL, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active- controlled clinical trial. Lancet. 2023;401(10388):1584–94. https://doi.org/10.1016/s0140-6736(23)00569-x.CrossRefPubMed

37.

Sparsentan. American journal of health-system pharmacy. 2023; 80(13):792–795. https://doi.org/10.1093/ajhp/zxad073.

38.

Barratt J, Rovin B, Wong MG, et al. IgA nephropathy patient baseline characteristics in the Sparsentan PROTECT Study. Kidney Int Rep. 2023;8(5):1043–56. https://doi.org/10.1016/j.ekir.2023.02.1086.CrossRefPubMedCentralPubMed

39.

Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6(5):859–66. https://doi.org/10.1111/j.1600-6143.2006.01288.x.CrossRefPubMed

40.

Lafayette RA, Canetta PA, Rovin BH, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28(4):1306–13. https://doi.org/10.1681/asn.2016060640.CrossRefPubMed

41.

Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435–45.CrossRefPubMed

42.

Sugiura H, Takei T, Itabashi M, et al. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract. 2011;117(2):C98–105. https://doi.org/10.1159/000319656.CrossRefPubMed

43.

Mallat SG, Itani HS, Abou-Mrad RM, Abou Arkoub R, Tanios BY. Rituximab use in adult primary glomerulopathy: where is the evidence? Ther Clin Risk Manag. 2016;12:1317–27. https://doi.org/10.2147/tcrm.S114316.CrossRefPubMedCentralPubMed

44.

Yang BY, Zhao M, Wu HJ, Lu QJ. A comprehensive review of biological agents for lupus: beyond single target. Front Immunol. 2020;11: 539797. https://doi.org/10.3389/fimmu.2020.539797.CrossRefPubMedCentralPubMed

45.

Lafayette RA, Rovin BH, Reich HN, Tumlin JA, Floege J, Barratt J. safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy. Kidney Int Rep. 2020;5(11):2032–41. https://doi.org/10.1016/j.ekir.2020.08.003.CrossRefPubMedCentralPubMed

46.

Maixnerova D, El Mehdi D, Rizk DV, Zhang H, Tesar V. New treatment strategies for IgA nephropathy: targeting plasma cells as the main source of pathogenic antibodies. J Clin Med. 2022;11(10):2810. https://doi.org/10.3390/jcm11102810.CrossRefPubMedCentralPubMed

47.

Zhao Q, Chen X, Hou Y, et al. Pharmacokinetics, pharmacodynamics, safety, and clinical activity of multiple doses of RCT-18 in Chinese. J Clin Pharmacol. 2016;56(8):948–59.CrossRefPubMed

48.

Barratt J, Lin C, Nawaz N, Molyneux K, Tumlin J A, Suzuki Y. FC051 atacicept reduces serum ANTI-GD-IGA1 levels in IgAN patients. Nephrol Dial Transpl. 2022;37(3):gfac107–13.

49.

Kim S-G, Vo N, Lee S-H, et al. FC052: atrasentan for the treatment of IGA nephropathy: interim results from the affinity study. Nephrol Dial Transpl. 2022;37(3):gfac107–14.

50.

Hegazy M, Darwish H, Darweesh H, El-Shehaby A, Emad Y. Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices. Clin Immunol. 2010;135(1):118–24. https://doi.org/10.1016/j.clim.2009.12.012.CrossRefPubMed

51.

Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253–65. https://doi.org/10.1002/art.11299.CrossRefPubMed

52.

Do RKG, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med. 2000;192(7):953–64. https://doi.org/10.1084/jem.192.7.953.CrossRefPubMedCentralPubMed

53.

Day ES, Cachero TG, Qian F, et al. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry. 2005;44(6):1919–31. https://doi.org/10.1021/bi048227k.CrossRefPubMed

54.

Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov. 2006;5(3):235–46. https://doi.org/10.1038/nrd1982.CrossRefPubMed

55.

Samy E, Wax S, Huard B, Hess H, Schneider P. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017;36(1):3–19. https://doi.org/10.1080/08830185.2016.1276903.CrossRefPubMed

56.

Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365–73. https://doi.org/10.1038/nrrheum.2014.33.CrossRefPubMed

57.

Ding J, Cai Y, Deng Y, et al. Telitacicept following plasma exchange in the treatment of subjects with recurrent NMOSD: study protocol for a single-center, single-arm, open-label study. Front Neurol. 2021;12:596791. https://doi.org/10.3389/fneur.2021.596791.CrossRefPubMedCentralPubMed

58.

Shiratori-Aso S, Nakazawa D, Nishio S, et al. Soluble interleukin-2 receptor predicts treatment outcome in patients with autoimmune tubulointerstitial nephritis. A preliminary study. Front Med. 2022;9:827388.CrossRef

59.

Io H, Hamada C, Fukui M, Horikoshi S, Tomino Y. Relationship between levels of urinary type IV collagen and renal injuries in patients with IgA nephropathy. J Clin Lab Anal. 2004;18(1):14–8.CrossRefPubMedCentralPubMed

60.

Yokoyama H, Wada T, Furuichi K, et al. Urinary levels of chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy. J Leukoc Biol. 1998;63(4):493–9. https://doi.org/10.1002/jlb.63.4.493.CrossRefPubMed

61.

Harada K, Akai Y, Kurumatani N, Iwano M, Saito Y. Prognostic value of urinary interleukin 6 in patients with IgA nephropathy: an 8-year follow-up study. Nephron. 2002;92(4):824–6. https://doi.org/10.1159/000065465.CrossRefPubMed

62.

Xie D, Zhao H, Xu X, et al. Intensity of macrophage infiltration in glomeruli predicts response to immunosuppressive therapy in patients with IgA nephropathy. J Am Soc Nephrol. 2021;32(12):3187–96. https://doi.org/10.1681/Asn.2021060815.CrossRefPubMedCentralPubMed

63.

Wu D, Li J, Xu D, Wang W, Li L, Fang J, Zhang F. A human recombinant fusion protein targeting B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL), telitacicept (RC18), in systemic lupus erythematosus (SLE): Results of a phase 2b study [abstract]. Arthritis Rheumatol. 2019;71(suppl 10):111.

64.

Chen X, Zhao Q, Hou Y, et al. Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis. Br J Clin Pharmacol. 2016;82(1):41–52. https://doi.org/10.1111/bcp.12908.CrossRefPubMedCentralPubMed

65.

Sun L, Shen Q, Gong Y, et al. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: a self-controlled before-after trial. Lupus. 2022;31(8):998–1006. https://doi.org/10.1177/09612033221097812.CrossRefPubMed

Title: Role of telitacicept in the treatment of IgA nephropathy
Authors: Lijun Wu
Xinru Du
Xuehong Lu
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01320-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Role of telitacicept in the treatment of IgA nephropathy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Analysis of the efficacy of a single subumbilical stoma for bilateral cutaneous ureterostomy after radical cystectomy

Therapeutic and adverse effects of adrenaline on patients who suffer out-of-hospital cardiac arrest: a systematic review and meta-analysis

Influence of perioperative blood pressure regulation on postoperative delirium in patients undergoing head and neck free flap reconstruction

Biofilm and wound healing: from bench to bedside

Effect of chewing gum on orthodontic pain in patients receiving fixed orthodontic treatment: a systematic review and meta-analysis

Soluble immune checkpoints are elevated in patients with primary biliary cholangitis